Intralesional Steroid Injection versus Erbium Yttrium Aluminium Garnet Laser Assisted Topical Corticosteroid Delivery in Treatment of Keloids.
- Disease/Condition
- Skin and Connective Tissue Diseases
- Intervention type
- other
- Primary sponsor
- Dina Hassan Abdeldayem
- Funder
- Dina Hassan Abdel Dayem
- Location
- Egypt
- Phase
- Phase 1
- Start date
- Aug 08, 2018
- End date
- Feb 07, 2019
Keloid scars are often considered aesthetically unattractive and frustrating problem that cause functional and cosmetic deformities, displeasure, itching, pain, and psychological stress and may possibly affect joint movement (Trisliana et al., 2014).With limited knowledge about the actual causes of keloids, determining the most effective treatment has been challenging. Various methods have been implemented to improve keloid scars using both surgical and non-surgical approaches such as intralesional corticosteroid injections, fractional lasers, cryosurgery, 5-fluorouracil (5-FU), retinoic acid, imiquimod 5% cream (an immune response modifier that enhances healing, has also been used to help prevent keloid recurrence after surgical excision)., tamoxifen, tacrolimus, botulinum toxin, silicone sheets (Berman, 2017).Fractional lasers have emerged as a therapeutic option for the aesthetic restoration and functional enhancement of traumatic scars. They create zones of ablation at variable depths, which induce a molecular cascade, including heat shock proteins and other factors that lead to a rapid healing response and prolonged neocollagenesis with subsequent collagen remodeling. The likely result is the removal of a portion of fibrotic scar tissue and a relative normalization of collagen structure and composition (Cavalié et al., 2015).Aim of studyTo compare a combination treatment modality consisting of fractional ablative laser treatment and topical corticosteroid application to the standard modality of corticosteroid intralesional injection.
- Registry
- Pan Africa Clinical Trials Registry
- Trial ID
- PACTR201909502724014
- Type
- Non-Device Trial
Access comprehensive clinical trial information for PACTR201909502724014 through Pure Global AI's free database. This Phase 1 trial is sponsored by Dina Hassan Abdeldayem and is currently Completed. The study focuses on Skin and Connective Tissue Diseases.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.